2008


  • Lamoureux F, Ory B, Battaglia S, Pilet P, Heymann MF, Gouin F, Duteille F, Heymann D, Rédini F. Relevance of a new rat syngenic model of osteoblastic metastases from prostate carcinoma for pre-clinical studies using zoledronic acid. Int J Cancer, 2008, 122: 751-760.
  • Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther, 2008, 8, 151-159.
  • Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers MJ, Heymann D. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med, 2008, 12, 928-941
  • Duplomb L, Baud'huin M, Charrier C, Berreur M, Trichet V, Blanchard F, Heymann D. Interleukin-6 inhibits receptor activator of nuclear factor kB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of serine727 phosphorylation of signal transducer and activator of transcription factor 3. Endocrinology, 2008, 149: 3688-3697.
  • Lamoureux F, Picarda G, Rousseau J, Gourden C, Battaglia S, Charrier C, Pitard B, Heymann D, Redini F. Therapeutic efficacy of soluble receptor activator of NF-kB delivered by non viral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther, 2008; 7: 3389-3398
  • Heymann MF, Riet A, Battaglia S, Paineau J, Heymann D. OPG,  RANK and RANK ligand expression in thyroid lesions. Regulatory Peptides, 2008, 148: 46-53
  • Brounais B, Chipoy C, Mori K, Charrier C, Battaglia S, Pilet  P, Richards CD, Heymann D, Redini F, Blanchard F. Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the anti-tumor effect of midostaurin in vivo. Clin Cancer Res, 2008; 14: 5400-5409.
  • Ando K, Mori K, Redini F, Heymann D. RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol, 2008; 5: 263-268.
  • Mori K, Rédini F, Blanchard F, Charrier C, Battaglia S, Duplomb L, Ando K, Shultz L, Redini F, Heymann D. Conditioned medium from osteosarcoma cells up-regulated MC3T3-E1 osteoblastic cell proliferation via JAKs and PI3-K/Akt signal cross-talk. Cancer Sci, 2008; 99: 2170-2176.
  • Brounais B, Ruiz Veslasco C, Rousseau J, Lamoureux F, Blanchard F, Heymann D, Redini F. Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. Recent Patents on Anti-Cancer, Drug Discov, 2008; 3: 178-186.
  • Chauvin C, Philippeau JM, Hubert FX, Wittrant Y, Lamoureux F, Trinité B, Heymann D, Rédini F, Josien R. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res, 2008, 68: 9433-9440.
  • Morel J, Deschamps V, Toussirot E, Pertuiset E, Sordet C, Kieffer P, Berthelot JM, Champagne H, Mariette X, Combe B. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008, 67:244-247.
  • Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, Khammari A, Dréno B, Jacques Y, Blanchard F, Godard A. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes. J Pathol, 2008, 216: 451-459.
  • Berthelot JM, Tortellier L, Lavy-Bregeon D, Le Goff B, Maugars Y.High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies? Joint Bone Spine. 2008, 75:167-171. 
  • Gérard S, le Goff B, Maugars Y, Berthelot JM. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfilment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients. Joint Bone Spine. 2008, 75:680-687.

2007

  • Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D. Zoledronic acid activates the DNA S phase checkpoint and induces osteosarcoma cell death characterized by AIF and EndoGtranslocation in dependently of p53 and Rb status. Mol Pharmacol, 2007, 71: 333-343.
  • LacreusetteA, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, JacquesY, Godard A, Blanchard F.  Loss of Oncostatin M receptor b in metastatic melanoma cells. Oncogene, 2007, 26: 881-892.
  • Key roles of the OPG-RANK-RANKL system in bone oncology. Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M. ExpertRev Anticancer Ther, 2007, 7: 221-232
  • Lamoureux F, Trichet V, Chipoy C, Blanchar F, Gouin F, Redini F. Recent advances in themanagement of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther, 2007, 7:169-181. 
  • Duplomb L, DagouassatM, Jourdon P, Heymann D. Embryonic stem cells: new tools to study osteoblast and osteoclast differentiation. Stem Cells,  2007, 25: 544-552.
  • Mori K,Berreur M, Le Goff B, Riet A, Moreau A, Blanchard F, Chevalier C,Guisle-Marsollier I, Léger J, Guicheux J, Masson M, Gouin F, Rédini F, Heymann D.  Human osteosarcoma cells express functional Receptor Activator of Nuclear Factor-kappa B. J Pathol, 2007: 211:555-562. 
  • Mori K, LeGoff B, Charrier C, Battaglia S, HeymannD, Rédini F. DU145 human prostate cancer cells express functional receptor activator of NFkB: new insights in the prostate cancer bone metastasis process. Bone, 2007, 40:981-990. 
  • Duplomb L, Dagouassat M, Jourdon P, Heymann D. Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoïd body. In vitro Cell Dev Biol: animals, 2007, 43: 21-24. 
  • Ory B, Moriceau G, Rédini F, Heymann D. mTOR inhibitors (rapamycin and derivatives) and nitrogen-bisphosphonates: bi-functional compounds for the treatment of bone tumors. Current Medicinal Chemistry, 2007,14: 1381-1387
  • Lamoureux M, Baud'huin M, Duplomb L, Heymann D, Rédini F. Proteoglycans : key partners of the Bone cell biology. Bioessays, 2007, 29:758-771. 
  • Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D.  RANKL, RANK, Osteoprotegerin: keypartners of osteoimmunology and vascular diseases. Cellular and Molecular Life Sciences, 2007, 64: 2334-2350.
  • Chipoy C, Brounais B, Trichet V, Battaglia S, Berreur M, Oliver L, Juin P, Rédini F, Heymann D, Blanchard F. Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene, 2007, 26: 6653-6664. 
  • Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, Pitard B, Heymann D, Rédini F.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: prevention of bone resorption, inhibition of tumor progression, increase of animal survival. Cancer Res, 2007, 67: 7308-7318 
  • Perrot P, Heymann D, Rédini F, Charrier C, Couillaud S, Duteille F. Extraosseous bone formation obtained by association of mesenchymal stem cells and a periosteal flap in the rat. Ann Plat Surg, 2007, 59: 201-206. 
  • Mori K, Berreur M, Blanchard F, Chevalier C, Guisle-Marsollier I, Masson M, Rédini F, Heymann D. Receptor Activator of Nuclear Factor-kB Ligand (RANKL) directly modulates gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncology Reports, 2007, 18: 1365-1371. 
  • Mori K, Heymann D, Le Bot R.  Bone modulating bioactive natural compounds: review. Curr Bioactive Compounds, 2007, 3: 193-200.
  • Wuillème-Toumi S, Trichet V, Gomez-Bougie P, Gratas C, Bataille R, Amiot M. Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochem Biophys Res Commun. 2007, 361:865-869.
  • Romagnoli M, Trichet V, David C., Clement M., Moreau P., Bataille R., Barillé-Nion S. Significant impact of survivin on myeloma cell growth. Leukemia 2007, 21: 1070-1078.


2006

  • Mori K, Rédini F, Gouin F, Cherrier B, Heymann D. Osteosarcoma : current status of immunotherapy and future trends. Oncol Rep, 2006, 15 : 693-700.
  • Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D, Rédini F.  RANKL directly induces bone morphogenetic protein-2 expression in RANK-expression POS-1 osteosarcoma cells. Int J Oncol, 2006, 28: 261-269.
  • Heymann D Autophagy and inflammation: a protective mechanism in response to the stress. Current Opin Invest Drugs, 2006, 7: 443-450.
  • Gouin F, Rédini F, Ory B, Heymann D. Zoledronic acid slowdowns rat chondrosarcoma progression, increases overall survival and delays tumor recurrence after intralesional curettage. Int J Cancer, 2006, 119:980-984.
  • Kwan Tat S, Padrines M, Théoleyre S, Battaglia S, Heymann D, Redini F, Fortun Y. OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone, 2006, 39:706-715.
  • Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with Receptor Activator of Nuclear Factor kB Ligand (RANKL) and RANK.  Biochem Biophys Res Commun, 2006, 347:460-467
  • Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Thierry H, Collette M, Robillard N, Bataille R, Amiot M. CD45negative but not CD45positive human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol, 2006, 177: 4218-4223.
  • Trichet V, Benezech C, Dousset C, Gesnel MC, Bonneville M, Breathnach R Complex interplay of activating and inhibitory signals received by V_9V_2 T cells revealed by target cell b2-microglobulin knockdown. J Immunol, 2006, 177: 6129-6136.

2005

  • Heymann D, Fortun Y, Rédini F, Padrines M. Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools to the standard bisphosphonates. Drug Discov Today, 2005, 10: 242-247.
  • Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases. Drug Discov Today, 2005, 10:197-204.
  • Cherrier B, Gouin F, Thiéry JP, Rédini F, Heymann D, Duteille F. A new experimental rat model of osteosarcoma established by intra-femoral tumor cell inoculation, useful for biology and therapy investigations.  Tumor Biol, 2005, 26: 121-130.
  • Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thièry JP, Gouin F, Rédini F. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.  Bone, 2005, 37: 74-86.
  • Romih M, Delécrin J, Heymann D, Passuti N. The vertebral interbody grafting site's low concentration in osteogenic progenitors can greatly benefit from addition of iliac crest bone marrow . Eur Spine J, 2005, 14 : 645-648.
  • Théoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Rédini F, Heymann D.  Phenotypic and functional analysis of lymphocytes infiltrating bone-associated tumors: use as a new therapeutic approach of osteosarcoma. BMC Cancer, 2005, 5 : 123 (1-10).
  • Ory B, Heymann MF, Blanchard F, Kamijo A, Gouin F, Heymann D, Rédini F. Zoledronic acid suppresses lung metastases and extends overall survival of osteosarcoma of osteosarcoma-bearing mice. Cancer, 104: 2522-2529.

2004

  • Advantage of using intercostal vessels as recipient site for free flaps covering lumbar defect. Duteille F, Perrot P, Floch N, Pannier M.  J Reconstr Microsurg, 2004, 20 : 523-526.
  • Evaluation of the advantages of Integra for covering radial forearm flap donor sites. Duteille F, Perrot P, Pannier P.  A series of 10 cases. Plast Reconstr Surg, 2004, 114: 264-266.
  • Relevance of an in vitro osteoclastogenesis to study Receptor Activator of NF-kB Ligand (RANKL) and osteoprotegerin (OPG) biological activities? Wittrant Y, Théoleyre S, Couillaud S, Dunstan C, Charrier C, Heymann D, Rédini F. Exp Cell Res, 2004, 293: 292-301.
  • Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of Receptor Activator of Nuclear Factor kB Ligand and MAPK. Théoleyre S, Wittrant Y, Couillaud S, Vusio P, Berreur M, Dunstan C, Blanchard F, Rédini F, Heymann D.  Biochim Biophys Acta Mol Cell Res, 2004, 1644:1-7.
  • IL-6, RANKL, TNF-alpha/IL-1:interrelations in bone resorption pathophysiology. Kwan Tat S, Padrines M, Théoleyre S, Heymann D, Fortun Y.  Cytokine Growth Factor Rev, 2004, 15: 49-60.
  • Bisphosphonates : new therapeutic agents for the treatment of bone tumors. Heymann D, Ory B, Gouin F, Green J, Rédini F. Trends Mol Med, 2004, 10: 337-343.
  • RANKL/RANK/OPG:new therapeutic targets in bone tumors and associated osteolysis. Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Rédini F. Biochimica Biophysica Acta Rev on Cancer, 2004, 1704: 49-57.
  • Down-regulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells required PKCd and STAT3. Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C, Rédini F, Heymann D, Blanchard F.  J Bone Miner Res, 2004, 19: 1850-1861.
  • OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling.Théoleyre S, Wittrant Y, Kwan Tat S, Fortun Y, Redini F, Heymann D. The molecular triad  Cytokine Growth Factor Rev, 2004, 15: 457-475.

2003

  • Soluble mannose6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibitsinterleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II. Duplomb L, Chaigne-Delalande B, Vusio P, Raher S, Jacques Y, Godard A, Blanchard F.  Endocrinology, 2003, 144: 5381-5389.
  • DNA methylation controlsthe responsiveness of hepatoma cells to leukemia inhibitory factor. Blanchard F, Tracy E, Smith J,Chattopadhyay S, Wang Y, Held WA, Baumann H. Hepatology, 2003, 38: 1516-1528.
  • Hamstring insertion site healingafter anterior cruciate ligament reconstruction in patients withsymptomatic hardware or repeat rupture: a histologic study in 12patients. Robert H, Es-Sayeh J, HeymannD, Passuti N, Eloit S, Vaneenoge E. Arthroscopy, 2003, 19: 948-954.
  • Management of complex interphalangeal joint fractures bydynamic external traction- A series of 20 cases. Duteille F, Pasquier P, Lim A,Dautel G.  Plast Reconstr Surg, 2003, 15: 1623-1629.
  • Are metatarsal giant cell tumours and giant-cell reparative granuloma different entities ? A clinical, pathological, ultrastructural and in vitro resorption ability analysisof two cases. Gouin F, Grimaud E, Rédini F, Moreau A, Passuti N, Heymann D. Clin Orthop Rel Res, 2003, 416: 278-284.
  • Regulation of osteoclast protease expression by RANKL. Wittrant Y, Théoleyre S, Couillaud S, Dunstan C, Charrier C, Heymann D, Rédini F. Biochem Biophys Res Commun, 2003, 310: 774-778.
  • Receptor Activator of Nuclear Factor kB Ligand(RANKL)/Osteoprotegerin (OPG) ratio is increased in severe osteolysis. Grimaud E, Soubigou L,Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Rédini F, HeymannD. Am J Pathol, 2003, 163: 2021-2031.

2002

  • Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Grimaud E, Heymann D, Rédini F.Cytokine Growth Factor Rev, 2002, 13: 241-257.
  • Osteoclastic acidification pathways during bone resorption. Rousselle AV, Heymann D.  Bone, 2002, 30: 533-540.
  • Influence of metal ion solutions on rabbit osteoclast activities in vitro. Rousselle AV, Heymann D, Demais V, Charrier C, Passuti N, Baslè MF. HistolHistopathol, 2002, 4: 1025-1032.
  • Bone remodeling and tumour grade modifications induced by interactions between bone andswarm rat chondrosarcoma. Grimaud E, Damiens C, Rousselle AV, Passuti N, Heymann D , Gouin F.  Histol Histopathol, 2002, 4: 1103-1111.
  • Osteoprotegerin differentially regulates protease expression in osteoclast cultures.Wittrant Y, Couillaud S, Théoleyre S, Dunstan C, Heymann D, Rédini F. Biochem Biophys Res Commun, 2002, 293: 38-44.
  • Targeting destruction of the DNA protein cdc6 by cell death pathways inmammals and yeast. Blanchard F, Rusiniak M, SharmaK, Sun XL, Todarov I, Castellano M, Gutierrez C, Baumann H, Burhans WC.Mol Cell Biol, 2002, 13: 1536-1549.
  • Leukemiainhibitroy factor (LIF) is expressed in hypertrophic chondrocytes andin vascular sproots during osteogenesis. Grimaud E, Blanchard F, Charrier C, Gouin F, Rédini F, Heymann D.  Cytokine, 2002, 20: 224-230.
  • Complex evolution of vitellogenin genes in salmonid fishes. Buisine N, Trichet V, Wolff J. Mol GenetGenomics, 2002, 268: 535-542.

2001

  • Influence of bone environment on ceramicosteointegration in spinal fusion: comparison of bone-poor andbone-rich sites. Delécrin J, Deschamps C, Romih M, Heymann D, Passuti N.  Eur Spine J, 2001, 10: S110-S113.
  • Osteoprotegerin : a new therapeutic agent for the treatment of bonedisease. Grimaud E, Rédini F, Heymann D. Drug Discov Today, 2001, 6: 1241-1242.
  • Potential synergies between matrixproteins and soluble factors on resorption and proteinase activities of rabbit bone cells. Rousselle AV, Damiens C, Fortun Y, Passuti N, Padrines M, Heymann D.  Histol Histopathol, 2001, 16: 727-734.
  • Ultrastructural evidence in vitro of osteoclast-induced degradation of calcium phosphate ceramic by simultaneous resorption and phagocytosis mechanisms. Heymann D, Guicheux J, Rousselle AV.  Histol Histopathol, 2001, 16: 37-44.
  • A composite element binding the vitamin D receptor and the retinoic X receptor a mediates the transforming growth factor-beta inhibition of decorin gene expression in articular chondrocytes. Demor-Fossard M, Galera P, Santra M, Iozzo RV, Pujol JP, Redini F. J Biol Chem, 2001, 276:36983-92
  • Identification of agonistic andantagonistic antibodies against gp 190, the leukemia inhibitory factorreceptor, reveals distinct roles for its two cytokine binding domains. Taupin JL, Legembre P, Bitard J, Daburon S, Pitard S, Blanchard F, Duplomb L, Godard A, Jacques Y, Moreau JF. J Biol Chem, 2001, 276: 47975-47981.
  • Oncostatin M regulates synthesis andturnover of gp 130, leukemia inhibitory factor receptor ± andoncostatin M receptor beta by distinct mechanisms. Blanchard F, Wang Y, Kinzie E,Duplomb L, Godard A, Baumann H.  J Biol Chem, 2001,276: 47038-47045.

2000

  • Differentiation of mucous neck cells into parietal cells: a newconcept of mitochondrial biogenesis. Pradal G, Berreur M, Pouyet B,Riet A. Biol Cell, 2000, 92 :545-554.
  • Human growth hormone stimulatesproteinase activities of rabbit bone cells via IGF-1. Rousselle AV, Damiens C, FortunY, Passuti N, Padrines M, Heymann D. Biochem BiophysRes Commun, 2000, 268: 875-881.
  • Cysteine proteaseproduction by human osteosarcoma cells (MG63, SaOS2) and its modulationby soluble factors. Damiens C, Grimaud E, Rousselle AV, Charrier C, Fortun Y, Heymann D, Padrines M.  Cytokine, 2000, 12: 539-542.
  • Modulation by soluble factors of gelatinaseactivities released by osteoblastic cells. Damiens C, Fortun Y, CharrierC, Heymann D, Padrines M. Cytokine, 2000, 12:1727-1731.
  • gp130 cytokine family and bone cells. Heymann D, Rousselle AV.  Cytokine, 2000, 12: 1455-1468.
  • Inhibition of apatite formation by vitronectin. PadrinesM, Rohanizadeh R, Damiens C, Heymann D, Fortun Y.  Connect Tissue Res, 2000, 41: 101-108.
  • Characterization of the human tubulin tyrosine ligase-like 1gene (TTLL1) mapping to 22q13.1. Trichet V, Ruault M, Roizes G, DeSario A. . Gene, 2000, 257: 109-117.
  • Genomic analysis of thevitellogenin locus in rainbow trout (Oncorhynchus mykiss) reveals acomplex history of gene amplification and retroposon activity. Trichet V, Buisine N, MouchelN, Moran P, Pendas AM, Le Pennec JP, Wolff J. Mol GenGenet, 2000, 263: 828-837.
  • Semiquantitative reversetranscription-polymerase reaction analysis of syndecan-1 and -4messages in cartilage and cultured chondrocytes from osteoarthriticjoints. Barré PE, Rédini F, BoumedieneK, Vielpeau C, Pujol J-P. Osteoarthritis Cartilage, 2000, 8: 34-43.
  • Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. Wang Y, Robledo O, Kinzie E, Blanchard F, Richards C, Miyajima A, Baumann H.  J Biol Chem, 2000, 275:25273-25285.
  • Stimulation of leukemia inhibitory factor receptor. Degradation by extracellular signal-regulated kinase. Blanchard F, Duplomb L, Wang Y,Robledo O, Kinzie E, Pitard V, Godard A, Jacques Y, Baumann H. J Biol Chem, 2000, 275:28793-28801.